Prijava na doktor.rs mailing listu
Pratite nas redovno putem newslettera.

Sva vremena su u UTC + 2 sata




Započni novu temu Odgovori na temu  [ 3 Posta ] 
Autoru Poruka
 Tema posta: vitiligo i kancer koze
PostPoslato: Sre Sep 27, 2006 10:07 pm 
OffLine
Novi član
Novi član

Pridružio se: Pet Sep 22, 2006 12:41 am
Postovi: 25
Pozdrav svima,
da sam trebala ovu temu da postavim pre godinu dana (isti naslov) , ne bih se usudila jer me je uzasavala i sama pomisao na ovu bolest. Zivela sam u uverenju da su ljudi koji imaju vitiligo u vecoj opasnosti da obole od raka koze od drugih.Medjutim poslednja vitiligo konferencija je iznela najnovija istazivanja vezana za ovu temu.
ovde je originalan tekst:

FROM FORBES.COM

BusinessWire
GammaCan Participates in 2006 Vitiligo Support National Conference; Company Joins Community in Exploring Treatment Alternatives, Pathology, New Research, Autoimmune Diseases and the Potential of Assisting in the Treatment of Malignant Melanoma

07.26.06, 7:33 AM ET

GammaCan International (OTC BB:GCAN) today announced that Patrick Schnegelsberg, CEO, participated at and presented at the 2006 Vitiligo Support National Conference held at the Hilton Universal City near Los Angeles in California from July 14th through the 16th.

The conference featured individuals with vitiligo, physicians and other experts in vitiligo treatments, pathology, new research, autoimmune diseases and more.

"GammaCan is aiming at becoming actively involved and work with the vitiligo community. In addition, we are exploring if we could be in a position to provide needed options to the vitiligo community while at the same time assisting patients suffering from metastatic malignant melanoma. VitiGam, an innovative anti-cancer product designed to treat Stage III and IV melanoma, may play a role here," stated Patrick Schnegelsberg.

About VitiGam:

VitiGam is GammaCan's second generation intravenous IgG-based product and a first-in-class anti-cancer immunotherapy. GammaCan plans on having VitiGam enter phase I/II testing under a US IND in the near future after recently holding a pre-IND meeting with the FDA. VitiGam is being designed to target metastatic melanoma patients with Stage III and IV melanoma. VitiGam is an IgG product that is different from standard IgGs: It is manufactured from the plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population. GammaCan scientists have shown that this "enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma activity in both in vitro and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to provide (1) anti-melanoma activity directed specifically against malignant melanoma cells and (2) non-specific anti-cancer activity - as is the case with IgG in general.

About Vitiligo Support International:

Vitiligo Support International, the largest vitiligo organization in the world, is a global community organization committed to supporting those affected by vitiligo, raising awareness, promoting research, and discussing effective treatments until a cure is found. Their website is at www.VitiligoSupport.org

About GammaCan:

GammaCan is focusing on the commercialization of an innovative anti-cancer immunotherapy to treat metastatic cancer. GammaCan's platform is based on IVIg, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. IVIg works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. GammaCan is developing VitiGam, its second generation program. VitiGam is an IVIg derived from the plasma of vitiligo donors and is being developed to treat malignant melanoma. GammaCan owns, and has applied for US patent protection covering the use of IVIg and vitiligo-derived IVIg (VitiGam).

For more information about GammaCan visit www.GammaCan.com or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free 1-866-308-0396 (from North America).

Safe Harbor Statement:

Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IVIg into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early state medical research and development companies filed with the SEC on Edgar.



--------------------------------------------------------------------------------

PRESS RELEASE

GammaCan Announces Appointment of Richard Spritz, M.D. To Scientific Advisory Board; Leading Genetic
Sep 05, 07:34 AM


GammaCan International (OTCBB: GCAN) today announced the appointment of Richard Spritz, M.D. to the Company's Scientific Advisory Board.

Bringing over thirty years of medical and scientific acumen to GammaCan, and specifically to the Company's mission of bringing VitiGam to the clinic, Dr. Spritz is a member of the Medical Advisory Board of Vitiligo Support International and a Council Member of PanAmerican Pigment Cell Society.

"We are extremely pleased that Richard has joined our Scientific Advisory Board and are honored by his participation. Richard's work on the identification and cloning of genes involved in the pathogenesis vitiligo is groundbreaking and undoubtedly will lead to new insights into this and other immune-mediated disorders. We both recognized the connection between our respective research efforts, and the entire Team at GammaCan is exited to work with Richard as we develop VitiGam to treat stage III and IV melanoma," stated Patrick Schnegelsberg, CEO.

Dr. Spritz is presently Director Human Medical Genetics Program and Professor of Pediatrics, Biochemistry and Molecular Genetics at the University of Colorado Health Science Center. Prior to his tenure at the University of Colorado, Dr. Spritz served as Assistant and Associate Professor of Medical Genetics and Pediatrics at the University of Wisconsin. Among his numerous accomplishments, Dr. Spritz sits on the Medical Advisory Board of Vitiligo Support International, is a member of The Council, PanAmerican Pigment Cell Society, Chaired a number of NIH Committees, and has for many years served on National Research Advisory Committees for the March of Dimes Birth Defects Foundation. He has been published over 170 peer-reviewed papers and receives ongoing research support from the NIH, specifically in the genetics of human pigmentation and autoimmune disorders. Richard Spritz holds an M.D. from Pennsylvania State University and was a Fellow in Human Genetics at the Yale University School of Medicine.

"I am delighted to be associated with GammaCan, and look forward to contributing to the company's efforts, to develop VitiGam. I believe this has the potential to be an important therapeutic to help patients suffering from advanced melanoma," said Spritz.

About VitiGam:

VitiGam is GammaCan's second generation intravenous IgG-based product and a first-in-class anti-cancer immunotherapy. GammaCan plans on having VitiGam to enter phase I/II testing under a US IND in the near future after it recently held a pre-IND meeting with the FDA. VitiGam is being designed to target metastatic melanoma patients with Stage III and IV melanoma. VitiGam is an IgG product that is different from standard IgGs: It is manufactured from the plasma of donors with vitiligo, a benign autoimmune skin condition affecting up to 2% of the general population. GammaCan scientists have shown that this "enriched" vitiligo IgG (VitiGam) contains potent anti-melanoma activity in both in vitro and mouse xenograft melanoma models. Thus, GammaCan expects VitiGam to provide (1) anti-melanoma activity directed specifically against malignant melanoma cells and (2) non-specific anti-cancer activity - as is the case with IgG in general.

About GammaCan:

GammaCan is a biopharmaceutical company focused on clinical-phase development and commercialization. GammaCan's initial therapy under development is a first-in-class anti-cancer immunotherapy aimed at preventing metastasis (the spread of cancer to other parts of the body) of a variety of cancers. GammaCan's first generation product (GCAN101) is currently completing phase II - clinical trials.

For more information about GammaCan visit www.GammaCan.com or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free 1-866-308-0396 (from North America).


Vrh
 Profil  
 
 Tema posta: Selling my domain.thanks to all.
PostPoslato: Sub Jan 28, 2012 9:10 am 
OffLine
Novi član
Novi član

Pridružio se: Čet Jan 26, 2012 5:47 pm
Postovi: 2
Hello to all on www.doktor.rs. Just letting everyone know house cleaning Las Vegas is for sale. I would consider any fairt offer. Have a awesome day!


Vrh
 Profil  
 
 Tema posta: Re: vitiligo i kancer koze
PostPoslato: Pon Feb 27, 2012 3:53 pm 
OffLine
Novi član
Novi član

Pridružio se: Pet Feb 24, 2012 3:10 pm
Postovi: 45
Sta s onima koji ne citaju engleski???


Vrh
 Profil  
 
Prikaži postove u poslednjih:  Poređaj po  
Započni novu temu Odgovori na temu  [ 3 Posta ] 


Sva vremena su u UTC + 2 sata


Ko je OnLine

Korisnici koji su trenutno na forumu: Nema registrovanih korisnika i 13 gostiju


Ne možete postavljati nove teme u ovom forumu
Ne možete odgovarati na teme u ovom forumu
Ne možete monjati vaše postove u ovom forumu
Ne možete brisati vaše postove u ovom forumu

Pronađi:
Idi na:  
Powered by phpBB © 2000, 2002, 2005, 2007 phpBB Group
 
Besplatno preuzmite doktor.rs aplikaciju za Vaš Android uređaj!
Ili skenirajte QR kôd sa vašim Android uređajem za najbrže preuzimanje: